Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
|Articles|April 14, 2023
Pharma USA 2023: Digital Therapeutics and Pharma
Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.
Advertisement
Tracey Dodenhoff, CEO of Medly Therapeutics, discusses her company's heart failure app and why pharma should consider prescription digital therapeutics among their offerings.
Advertisement
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
FDA Pauses Commissioner’s National Priority Voucher Program: Report
3
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
4
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
5